

# Global Thromboembolic Prevention Agent Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GFADDC0AAEFFEN.html>

Date: June 2026

Pages: 126

Price: US\$ 4,480.00 (Single User License)

ID: GFADDC0AAEFFEN

## Abstracts

The global Thromboembolic Prevention Agent market size is expected to reach \$ 47448 million by 2032, rising at a market growth of 4.7% CAGR during the forecast period (2026-2032).

Thromboembolic Prevention Agent refers to a class of essential therapeutic drugs and integrated treatment solutions that prevent venous and arterial thromboembolic events by inhibiting coagulation factor activity, reducing platelet aggregation, or interfering with thrombus formation processes. These therapies are widely used in the management of deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, ischemic stroke, coronary artery disease, cancer-associated thrombosis, and perioperative thrombosis prevention. The category includes heparins, vitamin K antagonists, direct oral anticoagulants (DOACs), factor Xa inhibitors, and antiplatelet agents, and is increasingly evolving toward long-term chronic disease management and precision anticoagulation strategies. Driven by global population aging, the rising prevalence of cardiovascular diseases, and growing demand for long-term outpatient healthcare management, thromboembolic prevention agents have evolved from traditional inpatient therapies into comprehensive chronic care solutions covering prevention, treatment, and long-term disease management. In recent years, innovations focused on lower bleeding risk, oral administration, long-acting formulations, and digital healthcare integration have positioned the Thromboembolic Prevention Agent market as one of the most stable-growth and investment-attractive segments within the global cardiovascular and chronic disease treatment industry. The average gross profit margin of this product is 75%.

The continued acceleration of global aging, increasing prevalence of atrial fibrillation and venous thromboembolism, and ongoing expansion of chronic disease management

systems are driving the thromboembolic prevention agent market into a long-term growth cycle. In recent years, novel oral anticoagulants such as DOACs have rapidly penetrated both hospital and outpatient markets due to lower monitoring requirements and improved safety profiles, accelerating the industry's transition from traditional injectable anticoagulation toward long-term oral management solutions. At the same time, rising volumes of orthopedic surgeries, cancer therapies, and minimally invasive interventions are further increasing demand for perioperative antithrombotic prevention. Government chronic disease initiatives, broader reimbursement coverage, and the development of internet healthcare platforms are also accelerating the industry's evolution toward digitalized, precision-oriented, and long-term healthcare management models.

Despite strong market demand, the thromboembolic prevention agent industry continues to face challenges related to bleeding risk management, insufficient long-term patient adherence, and the complexity of individualized anticoagulation strategies. Antithrombotic therapy requires precise balancing between thrombosis prevention and bleeding avoidance, placing high demands on drug safety and clinical monitoring capabilities. In addition, lengthy R&D cycles for novel anticoagulants, intense global patent competition, and increasingly stringent regulatory standards continue to raise industry entry barriers. In recent years, fluctuations in global pharmaceutical supply chains and shortages of certain raw materials have also created supply stability pressures for high-end anticoagulant products.

Downstream demand is gradually evolving from acute inpatient treatment toward long-term outpatient chronic disease management, home healthcare, and digital medical applications. Rising demand for long-term antithrombotic treatment among atrial fibrillation patients, elderly populations, oncology patients, and post-surgical recovery groups is making oral anticoagulation strategies increasingly dominant. Meanwhile, growing patient demand for reduced hospitalization frequency, less coagulation monitoring, and greater treatment convenience is further accelerating DOAC market expansion. The rapid development of internet hospitals, remote follow-up platforms, and AI-driven chronic disease management systems is transforming the industry from simple pharmaceutical supply into integrated "drug + monitoring + digital health" management ecosystems.

This report studies the global Thromboembolic Prevention Agent demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for

Thromboembolic Prevention Agent, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Thromboembolic Prevention Agent that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Thromboembolic Prevention Agent total market, 2021-2032, (USD Million)

Global Thromboembolic Prevention Agent total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Thromboembolic Prevention Agent total market, key domestic companies, and share, (USD Million)

Global Thromboembolic Prevention Agent revenue by player, revenue and market share 2021-2026, (USD Million)

Global Thromboembolic Prevention Agent total market by Type, CAGR, 2021-2032, (USD Million)

Global Thromboembolic Prevention Agent total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Thromboembolic Prevention Agent market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, Eisai Co Ltd, Sun Pharmaceutical, Teva, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Thromboembolic Prevention Agent market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

### Global Thromboembolic Prevention Agent Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

### Global Thromboembolic Prevention Agent Market, Segmentation by Type:

Direct Oral Anticoagulants (DOACs)

Low Molecular Weight Heparins (LMWHs)

Vitamin k Antagonists (VKAs)

Factor Xa Inhibitors

Other

### Global Thromboembolic Prevention Agent Market, Segmentation by Mechanism Type:

Anticoagulation

Antiplatelet

Fibrinolytic

Factor Blocking

Global Thromboembolic Prevention Agent Market, Segmentation by Clinical Application:

DVT Prevention

PE Prevention

Stroke Prevention

Surgical Prophylaxis

Other

Global Thromboembolic Prevention Agent Market, Segmentation by Application:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Companies Profiled:

Bristol-Myers Squibb

Bayer

Pfizer

Johnson & Johnson

Sanofi

Boehringer Ingelheim

Daiichi Sankyo

Eisai Co Ltd

Sun Pharmaceutical

Teva

Fresenius

Jingzhou Pharma

Changzhou Qianhong

Viartis

Hepalink

#### Key Questions Answered

1. How big is the global Thromboembolic Prevention Agent market?
2. What is the demand of the global Thromboembolic Prevention Agent market?
3. What is the year over year growth of the global Thromboembolic Prevention Agent market?
4. What is the total value of the global Thromboembolic Prevention Agent market?
5. Who are the Major Players in the global Thromboembolic Prevention Agent market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Thromboembolic Prevention Agent Introduction
- 1.2 World Thromboembolic Prevention Agent Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Thromboembolic Prevention Agent Total Market by Region (by Headquarter Location)
  - 1.3.1 World Thromboembolic Prevention Agent Market Size by Region (2021-2032), (by Headquarter Location)
  - 1.3.2 United States Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.3 China Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.4 Europe Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.5 Japan Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.6 South Korea Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.7 ASEAN Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
  - 1.3.8 India Based Company Thromboembolic Prevention Agent Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Thromboembolic Prevention Agent Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Major Market Trends

### 2 DEMAND SUMMARY

- 2.1 World Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.2 World Thromboembolic Prevention Agent Consumption Value by Region
  - 2.2.1 World Thromboembolic Prevention Agent Consumption Value by Region (2021-2026)
  - 2.2.2 World Thromboembolic Prevention Agent Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.4 China Thromboembolic Prevention Agent Consumption Value (2021-2032)

- 2.5 Europe Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.6 Japan Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.7 South Korea Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.8 ASEAN Thromboembolic Prevention Agent Consumption Value (2021-2032)
- 2.9 India Thromboembolic Prevention Agent Consumption Value (2021-2032)

### **3 WORLD THROMBOEMBOLIC PREVENTION AGENT COMPANIES COMPETITIVE ANALYSIS**

- 3.1 World Thromboembolic Prevention Agent Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global Thromboembolic Prevention Agent Industry Rank of Major Players
  - 3.2.2 Global Concentration Ratios (CR4) for Thromboembolic Prevention Agent in 2025
  - 3.2.3 Global Concentration Ratios (CR8) for Thromboembolic Prevention Agent in 2025
- 3.3 Thromboembolic Prevention Agent Company Evaluation Quadrant
- 3.4 Thromboembolic Prevention Agent Market: Overall Company Footprint Analysis
  - 3.4.1 Thromboembolic Prevention Agent Market: Region Footprint
  - 3.4.2 Thromboembolic Prevention Agent Market: Company Product Type Footprint
  - 3.4.3 Thromboembolic Prevention Agent Market: Company Product Application Footprint
- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

### **4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: Thromboembolic Prevention Agent Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: Thromboembolic Prevention Agent Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
  - 4.1.2 United States VS China: Thromboembolic Prevention Agent Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: Thromboembolic Prevention Agent Consumption Value Comparison

4.2.1 United States VS China: Thromboembolic Prevention Agent Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Thromboembolic Prevention Agent Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Thromboembolic Prevention Agent Companies and Market Share, 2021-2026

4.3.1 United States Based Thromboembolic Prevention Agent Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Thromboembolic Prevention Agent Revenue, (2021-2026)

4.4 China Based Companies Thromboembolic Prevention Agent Revenue and Market Share, 2021-2026

4.4.1 China Based Thromboembolic Prevention Agent Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Thromboembolic Prevention Agent Revenue, (2021-2026)

4.5 Rest of World Based Thromboembolic Prevention Agent Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Thromboembolic Prevention Agent Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Thromboembolic Prevention Agent Revenue (2021-2026)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Thromboembolic Prevention Agent Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Direct Oral Anticoagulants (DOACs)

5.2.2 Low Molecular Weight Heparins (LMWHs)

5.2.3 Vitamin k Antagonists (VKAs)

5.2.4 Factor Xa Inhibitors

5.2.5 Other

5.3 Market Segment by Type

5.3.1 World Thromboembolic Prevention Agent Market Size by Type (2021-2026)

5.3.2 World Thromboembolic Prevention Agent Market Size by Type (2027-2032)

5.3.3 World Thromboembolic Prevention Agent Market Size Market Share by Type (2027-2032)

## **6 MARKET ANALYSIS BY MECHANISM TYPE**

6.1 World Thromboembolic Prevention Agent Market Size Overview by Mechanism

Type: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Mechanism Type

6.2.1 Anticoagulation

6.2.2 Antiplatelet

6.2.3 Fibrinolytic

6.2.4 Factor Blocking

6.3 Market Segment by Mechanism Type

6.3.1 World Thromboembolic Prevention Agent Market Size by Mechanism Type (2021-2026)

6.3.2 World Thromboembolic Prevention Agent Market Size by Mechanism Type (2027-2032)

6.3.3 World Thromboembolic Prevention Agent Market Size Market Share by Mechanism Type (2027-2032)

## **7 MARKET ANALYSIS BY CLINICAL APPLICATION**

7.1 World Thromboembolic Prevention Agent Market Size Overview by Clinical

Application: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Clinical Application

7.2.1 DVT Prevention

7.2.2 PE Prevention

7.2.3 Stroke Prevention

7.2.4 Surgical Prophylaxis

7.2.5 Other

7.3 Market Segment by Clinical Application

7.3.1 World Thromboembolic Prevention Agent Market Size by Clinical Application (2021-2026)

7.3.2 World Thromboembolic Prevention Agent Market Size by Clinical Application (2027-2032)

7.3.3 World Thromboembolic Prevention Agent Market Size Market Share by Clinical Application (2027-2032)

## **8 MARKET ANALYSIS BY APPLICATION**

8.1 World Thromboembolic Prevention Agent Market Size Overview by Application:

2021 VS 2025 VS 2032

## 8.2 Segment Introduction by Application

- 8.2.1 Hospital Pharmacies
- 8.2.2 Retail Pharmacies
- 8.2.3 Online Pharmacies

## 8.3 Market Segment by Application

- 8.3.1 World Thromboembolic Prevention Agent Market Size by Application (2021-2026)
- 8.3.2 World Thromboembolic Prevention Agent Market Size by Application (2027-2032)
- 8.3.3 World Thromboembolic Prevention Agent Market Size Market Share by Application (2021-2032)

## 9 COMPANY PROFILES

### 9.1 Bristol-Myers Squibb

- 9.1.1 Bristol-Myers Squibb Details
- 9.1.2 Bristol-Myers Squibb Major Business
- 9.1.3 Bristol-Myers Squibb Thromboembolic Prevention Agent Product and Services
- 9.1.4 Bristol-Myers Squibb Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
- 9.1.5 Bristol-Myers Squibb Recent Developments/Updates
- 9.1.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses

### 9.2 Bayer

- 9.2.1 Bayer Details
- 9.2.2 Bayer Major Business
- 9.2.3 Bayer Thromboembolic Prevention Agent Product and Services
- 9.2.4 Bayer Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
- 9.2.5 Bayer Recent Developments/Updates
- 9.2.6 Bayer Competitive Strengths & Weaknesses

### 9.3 Pfizer

- 9.3.1 Pfizer Details
- 9.3.2 Pfizer Major Business
- 9.3.3 Pfizer Thromboembolic Prevention Agent Product and Services
- 9.3.4 Pfizer Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
- 9.3.5 Pfizer Recent Developments/Updates
- 9.3.6 Pfizer Competitive Strengths & Weaknesses

### 9.4 Johnson & Johnson

- 9.4.1 Johnson & Johnson Details
- 9.4.2 Johnson & Johnson Major Business
- 9.4.3 Johnson & Johnson Thromboembolic Prevention Agent Product and Services
- 9.4.4 Johnson & Johnson Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
- 9.4.5 Johnson & Johnson Recent Developments/Updates
- 9.4.6 Johnson & Johnson Competitive Strengths & Weaknesses
- 9.5 Sanofi
  - 9.5.1 Sanofi Details
  - 9.5.2 Sanofi Major Business
  - 9.5.3 Sanofi Thromboembolic Prevention Agent Product and Services
  - 9.5.4 Sanofi Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
  - 9.5.5 Sanofi Recent Developments/Updates
  - 9.5.6 Sanofi Competitive Strengths & Weaknesses
- 9.6 Boehringer Ingelheim
  - 9.6.1 Boehringer Ingelheim Details
  - 9.6.2 Boehringer Ingelheim Major Business
  - 9.6.3 Boehringer Ingelheim Thromboembolic Prevention Agent Product and Services
  - 9.6.4 Boehringer Ingelheim Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
  - 9.6.5 Boehringer Ingelheim Recent Developments/Updates
  - 9.6.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
- 9.7 Daiichi Sankyo
  - 9.7.1 Daiichi Sankyo Details
  - 9.7.2 Daiichi Sankyo Major Business
  - 9.7.3 Daiichi Sankyo Thromboembolic Prevention Agent Product and Services
  - 9.7.4 Daiichi Sankyo Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
  - 9.7.5 Daiichi Sankyo Recent Developments/Updates
  - 9.7.6 Daiichi Sankyo Competitive Strengths & Weaknesses
- 9.8 Eisai Co Ltd
  - 9.8.1 Eisai Co Ltd Details
  - 9.8.2 Eisai Co Ltd Major Business
  - 9.8.3 Eisai Co Ltd Thromboembolic Prevention Agent Product and Services
  - 9.8.4 Eisai Co Ltd Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)
  - 9.8.5 Eisai Co Ltd Recent Developments/Updates
  - 9.8.6 Eisai Co Ltd Competitive Strengths & Weaknesses

## 9.9 Sun Pharmaceutical

### 9.9.1 Sun Pharmaceutical Details

### 9.9.2 Sun Pharmaceutical Major Business

### 9.9.3 Sun Pharmaceutical Thromboembolic Prevention Agent Product and Services

### 9.9.4 Sun Pharmaceutical Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.9.5 Sun Pharmaceutical Recent Developments/Updates

### 9.9.6 Sun Pharmaceutical Competitive Strengths & Weaknesses

## 9.10 Teva

### 9.10.1 Teva Details

### 9.10.2 Teva Major Business

### 9.10.3 Teva Thromboembolic Prevention Agent Product and Services

### 9.10.4 Teva Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.10.5 Teva Recent Developments/Updates

### 9.10.6 Teva Competitive Strengths & Weaknesses

## 9.11 Fresenius

### 9.11.1 Fresenius Details

### 9.11.2 Fresenius Major Business

### 9.11.3 Fresenius Thromboembolic Prevention Agent Product and Services

### 9.11.4 Fresenius Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.11.5 Fresenius Recent Developments/Updates

### 9.11.6 Fresenius Competitive Strengths & Weaknesses

## 9.12 Jingzhou Pharma

### 9.12.1 Jingzhou Pharma Details

### 9.12.2 Jingzhou Pharma Major Business

### 9.12.3 Jingzhou Pharma Thromboembolic Prevention Agent Product and Services

### 9.12.4 Jingzhou Pharma Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.12.5 Jingzhou Pharma Recent Developments/Updates

### 9.12.6 Jingzhou Pharma Competitive Strengths & Weaknesses

## 9.13 Changzhou Qianhong

### 9.13.1 Changzhou Qianhong Details

### 9.13.2 Changzhou Qianhong Major Business

### 9.13.3 Changzhou Qianhong Thromboembolic Prevention Agent Product and Services

### 9.13.4 Changzhou Qianhong Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.13.5 Changzhou Qianhong Recent Developments/Updates

### 9.13.6 Changzhou Qianhong Competitive Strengths & Weaknesses

## 9.14 Viatris

### 9.14.1 Viatris Details

### 9.14.2 Viatris Major Business

### 9.14.3 Viatris Thromboembolic Prevention Agent Product and Services

### 9.14.4 Viatris Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.14.5 Viatris Recent Developments/Updates

### 9.14.6 Viatris Competitive Strengths & Weaknesses

## 9.15 Hepalink

### 9.15.1 Hepalink Details

### 9.15.2 Hepalink Major Business

### 9.15.3 Hepalink Thromboembolic Prevention Agent Product and Services

### 9.15.4 Hepalink Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026)

### 9.15.5 Hepalink Recent Developments/Updates

### 9.15.6 Hepalink Competitive Strengths & Weaknesses

## 10 INDUSTRY CHAIN ANALYSIS

### 10.1 Thromboembolic Prevention Agent Industry Chain

### 10.2 Thromboembolic Prevention Agent Upstream Analysis

### 10.3 Thromboembolic Prevention Agent Midstream Analysis

### 10.4 Thromboembolic Prevention Agent Downstream Analysis

## 11 RESEARCH FINDINGS AND CONCLUSION

## 12 APPENDIX

### 12.1 Methodology

### 12.2 Research Process and Data Source

### 12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Thromboembolic Prevention Agent Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Thromboembolic Prevention Agent Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Thromboembolic Prevention Agent Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Thromboembolic Prevention Agent Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Thromboembolic Prevention Agent Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Thromboembolic Prevention Agent Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Thromboembolic Prevention Agent Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Thromboembolic Prevention Agent Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Thromboembolic Prevention Agent Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Thromboembolic Prevention Agent Players in 2025

Table 12. World Thromboembolic Prevention Agent Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Thromboembolic Prevention Agent Company Evaluation Quadrant

Table 14. Head Office of Key Thromboembolic Prevention Agent Players

Table 15. Thromboembolic Prevention Agent Market: Company Product Type Footprint

Table 16. Thromboembolic Prevention Agent Market: Company Product Application Footprint

Table 17. Thromboembolic Prevention Agent Mergers & Acquisitions Activity

Table 18. United States VS China Thromboembolic Prevention Agent Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Thromboembolic Prevention Agent Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Thromboembolic Prevention Agent Companies, Headquarters (States, Country)

- Table 21. United States Based Companies Thromboembolic Prevention Agent Revenue, (2021-2026) & (USD Million)
- Table 22. United States Based Companies Thromboembolic Prevention Agent Revenue Market Share (2021-2026)
- Table 23. China Based Thromboembolic Prevention Agent Companies, Headquarters (Province, Country)
- Table 24. China Based Companies Thromboembolic Prevention Agent Revenue, (2021-2026) & (USD Million)
- Table 25. China Based Companies Thromboembolic Prevention Agent Revenue Market Share (2021-2026)
- Table 26. Rest of World Based Thromboembolic Prevention Agent Companies, Headquarters (Province, Country)
- Table 27. Rest of World Based Companies Thromboembolic Prevention Agent Revenue (2021-2026) & (USD Million)
- Table 28. Rest of World Based Companies Thromboembolic Prevention Agent Revenue Market Share (2021-2026)
- Table 29. World Thromboembolic Prevention Agent Market Size by Type, (USD Million), 2021 & 2025 & 2032
- Table 30. World Thromboembolic Prevention Agent Market Size Value by Type (2021-2026) & (USD Million)
- Table 31. World Thromboembolic Prevention Agent Market Size by Type (2027-2032) & (USD Million)
- Table 32. World Thromboembolic Prevention Agent Market Size by Mechanism Type, (USD Million), 2021 & 2025 & 2032
- Table 33. World Thromboembolic Prevention Agent Market Size Value by Mechanism Type (2021-2026) & (USD Million)
- Table 34. World Thromboembolic Prevention Agent Market Size by Mechanism Type (2027-2032) & (USD Million)
- Table 35. World Thromboembolic Prevention Agent Market Size by Clinical Application, (USD Million), 2021 & 2025 & 2032
- Table 36. World Thromboembolic Prevention Agent Market Size Value by Clinical Application (2021-2026) & (USD Million)
- Table 37. World Thromboembolic Prevention Agent Market Size by Clinical Application (2027-2032) & (USD Million)
- Table 38. World Thromboembolic Prevention Agent Market Size by Application, (USD Million), 2021 & 2025 & 2032
- Table 39. World Thromboembolic Prevention Agent Market Size by Application (2021-2026) & (USD Million)
- Table 40. World Thromboembolic Prevention Agent Market Size by Application

(2027-2032) & (USD Million)

Table 41. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors

Table 42. Bristol-Myers Squibb Major Business

Table 43. Bristol-Myers Squibb Thromboembolic Prevention Agent Product and Services

Table 44. Bristol-Myers Squibb Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. Bristol-Myers Squibb Recent Developments/Updates

Table 46. Bristol-Myers Squibb Competitive Strengths & Weaknesses

Table 47. Bayer Basic Information, Manufacturing Base and Competitors

Table 48. Bayer Major Business

Table 49. Bayer Thromboembolic Prevention Agent Product and Services

Table 50. Bayer Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 51. Bayer Recent Developments/Updates

Table 52. Bayer Competitive Strengths & Weaknesses

Table 53. Pfizer Basic Information, Manufacturing Base and Competitors

Table 54. Pfizer Major Business

Table 55. Pfizer Thromboembolic Prevention Agent Product and Services

Table 56. Pfizer Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 57. Pfizer Recent Developments/Updates

Table 58. Pfizer Competitive Strengths & Weaknesses

Table 59. Johnson & Johnson Basic Information, Manufacturing Base and Competitors

Table 60. Johnson & Johnson Major Business

Table 61. Johnson & Johnson Thromboembolic Prevention Agent Product and Services

Table 62. Johnson & Johnson Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 63. Johnson & Johnson Recent Developments/Updates

Table 64. Johnson & Johnson Competitive Strengths & Weaknesses

Table 65. Sanofi Basic Information, Manufacturing Base and Competitors

Table 66. Sanofi Major Business

Table 67. Sanofi Thromboembolic Prevention Agent Product and Services

Table 68. Sanofi Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 69. Sanofi Recent Developments/Updates

Table 70. Sanofi Competitive Strengths & Weaknesses

Table 71. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors

- Table 72. Boehringer Ingelheim Major Business
- Table 73. Boehringer Ingelheim Thromboembolic Prevention Agent Product and Services
- Table 74. Boehringer Ingelheim Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 75. Boehringer Ingelheim Recent Developments/Updates
- Table 76. Boehringer Ingelheim Competitive Strengths & Weaknesses
- Table 77. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
- Table 78. Daiichi Sankyo Major Business
- Table 79. Daiichi Sankyo Thromboembolic Prevention Agent Product and Services
- Table 80. Daiichi Sankyo Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 81. Daiichi Sankyo Recent Developments/Updates
- Table 82. Daiichi Sankyo Competitive Strengths & Weaknesses
- Table 83. Eisai Co Ltd Basic Information, Manufacturing Base and Competitors
- Table 84. Eisai Co Ltd Major Business
- Table 85. Eisai Co Ltd Thromboembolic Prevention Agent Product and Services
- Table 86. Eisai Co Ltd Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 87. Eisai Co Ltd Recent Developments/Updates
- Table 88. Eisai Co Ltd Competitive Strengths & Weaknesses
- Table 89. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
- Table 90. Sun Pharmaceutical Major Business
- Table 91. Sun Pharmaceutical Thromboembolic Prevention Agent Product and Services
- Table 92. Sun Pharmaceutical Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 93. Sun Pharmaceutical Recent Developments/Updates
- Table 94. Sun Pharmaceutical Competitive Strengths & Weaknesses
- Table 95. Teva Basic Information, Manufacturing Base and Competitors
- Table 96. Teva Major Business
- Table 97. Teva Thromboembolic Prevention Agent Product and Services
- Table 98. Teva Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 99. Teva Recent Developments/Updates
- Table 100. Teva Competitive Strengths & Weaknesses
- Table 101. Fresenius Basic Information, Manufacturing Base and Competitors
- Table 102. Fresenius Major Business
- Table 103. Fresenius Thromboembolic Prevention Agent Product and Services
- Table 104. Fresenius Thromboembolic Prevention Agent Revenue, Gross Margin and

Market Share (2021-2026) & (USD Million)

Table 105. Fresenius Recent Developments/Updates

Table 106. Fresenius Competitive Strengths & Weaknesses

Table 107. Jingzhou Pharma Basic Information, Manufacturing Base and Competitors

Table 108. Jingzhou Pharma Major Business

Table 109. Jingzhou Pharma Thromboembolic Prevention Agent Product and Services

Table 110. Jingzhou Pharma Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 111. Jingzhou Pharma Recent Developments/Updates

Table 112. Jingzhou Pharma Competitive Strengths & Weaknesses

Table 113. Changzhou Qianhong Basic Information, Manufacturing Base and Competitors

Table 114. Changzhou Qianhong Major Business

Table 115. Changzhou Qianhong Thromboembolic Prevention Agent Product and Services

Table 116. Changzhou Qianhong Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 117. Changzhou Qianhong Recent Developments/Updates

Table 118. Changzhou Qianhong Competitive Strengths & Weaknesses

Table 119. Viatris Basic Information, Manufacturing Base and Competitors

Table 120. Viatris Major Business

Table 121. Viatris Thromboembolic Prevention Agent Product and Services

Table 122. Viatris Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 123. Viatris Recent Developments/Updates

Table 124. Viatris Competitive Strengths & Weaknesses

Table 125. Hepalink Basic Information, Manufacturing Base and Competitors

Table 126. Hepalink Major Business

Table 127. Hepalink Thromboembolic Prevention Agent Product and Services

Table 128. Hepalink Thromboembolic Prevention Agent Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 129. Hepalink Recent Developments/Updates

Table 130. Hepalink Competitive Strengths & Weaknesses

Table 131. Global Key Players of Thromboembolic Prevention Agent Upstream (Raw Materials)

Table 132. Global Thromboembolic Prevention Agent Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Thromboembolic Prevention Agent Picture

Figure 2. World Thromboembolic Prevention Agent Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Thromboembolic Prevention Agent Total Revenue (2021-2032) & (USD Million)

Figure 4. World Thromboembolic Prevention Agent Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World Thromboembolic Prevention Agent Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company Thromboembolic Prevention Agent Revenue (2021-2032) & (USD Million)

Figure 13. Thromboembolic Prevention Agent Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 16. World Thromboembolic Prevention Agent Consumption Value Market Share by Region (2021-2032)

Figure 17. United States Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 18. China Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 23. India Thromboembolic Prevention Agent Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Thromboembolic Prevention Agent by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Thromboembolic Prevention Agent Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Thromboembolic Prevention Agent Markets in 2025

Figure 27. United States VS China: Thromboembolic Prevention Agent Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Thromboembolic Prevention Agent Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Thromboembolic Prevention Agent Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Thromboembolic Prevention Agent Market Size Market Share by Type in 2025

Figure 31. Direct Oral Anticoagulants (DOACs)

Figure 32. Low Molecular Weight Heparins (LMWHs)

Figure 33. Vitamin k Antagonists (VKAs)

Figure 34. Factor Xa Inhibitors

Figure 35. Other

Figure 36. World Thromboembolic Prevention Agent Market Size Market Share by Type (2021-2032)

Figure 37. World Thromboembolic Prevention Agent Market Size by Mechanism Type, (USD Million), 2021 & 2025 & 2032

Figure 38. World Thromboembolic Prevention Agent Market Size Market Share by Mechanism Type in 2025

Figure 39. Anticoagulation

Figure 40. Antiplatelet

Figure 41. Fibrinolytic

Figure 42. Factor Blocking

Figure 43. World Thromboembolic Prevention Agent Market Size Market Share by Mechanism Type (2021-2032)

Figure 44. World Thromboembolic Prevention Agent Market Size by Clinical Application, (USD Million), 2021 & 2025 & 2032

Figure 45. World Thromboembolic Prevention Agent Market Size Market Share by Clinical Application in 2025

Figure 46. DVT Prevention

Figure 47. PE Prevention

Figure 48. Stroke Prevention

Figure 49. Surgical Prophylaxis

Figure 50. Other

Figure 51. World Thromboembolic Prevention Agent Market Size Market Share by Clinical Application (2021-2032)

Figure 52. World Thromboembolic Prevention Agent Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 53. World Thromboembolic Prevention Agent Market Size Market Share by Application in 2025

Figure 54. Hospital Pharmacies

Figure 55. Retail Pharmacies

Figure 56. Online Pharmacies

Figure 57. World Thromboembolic Prevention Agent Market Size Market Share by Application (2021-2032)

Figure 58. Thromboembolic Prevention Agent Industrial Chain

Figure 59. Methodology

Figure 60. Research Process and Data Source

## I would like to order

Product name: Global Thromboembolic Prevention Agent Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GFADDC0AAEFFEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFADDC0AAEFFEN.html>